Get the Stockscreener App
0.916
4.38%
-0.042
Intercure Ltd stock is traded at $0.916, with a volume of 4,560.
It is down -4.38% in the last 24 hours and down -2.44% over the past month.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
See More
Previous Close:
$0.958
Open:
$0.89
24h Volume:
4,560
Relative Volume:
0.08
Market Cap:
$52.35M
Revenue:
$117.93M
Net Income/Loss:
$5.00M
P/E Ratio:
6.9711
EPS:
0.1314
Net Cash Flow:
$-12.91M
1W Performance:
-5.57%
1M Performance:
-2.44%
6M Performance:
-4.59%
1Y Performance:
-38.93%
1-Day Range:
$0.89
$0.935
1-Week Range:
$0.89
$1.00
52-Week Range:
$0.68
$1.7698
Intercure Ltd Stock (INCR) Company Profile
Compare INCR vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCR
Intercure Ltd
|
0.916 | 54.75M | 117.93M | 5.00M | -12.91M | 0.1314 |
TAK
Takeda Pharmaceutical Co Adr
|
17.15 | 53.43B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.10 | 44.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.03 | 37.52B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.56 | 32.24B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
535.67 | 22.46B | 3.17B | 1.29B | 1.01B | 27.09 |
Intercure Ltd Stock (INCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-22 | Upgrade | Canaccord Genuity | Speculative Buy → Buy |
Intercure Ltd Stock (INCR) Latest News
Price to book forward of Intercure Ltd. – NASDAQ:INCR - TradingView
ETFs Investing in InterCure Ltd. Stocks - TradingView
Intercure Ltd. (INCR) Slides 3% as Support at $0.90 Comes Into FocusFibonacci Entry Signals - dars.gov.et
InterCure Ltd. Actuals & Estimates (TASE:INCR) - TradingView
Price to earnings forward of InterCure Ltd. – TASE:INCR - TradingView
InterCure Ltd. Actuals & Estimates (BOATS:INCR) - TradingView
Price to sales forward of InterCure Ltd. – TASE:INCR - TradingView
Enterprise value to EBITDA forward of InterCure Ltd. – TASE:INCR - TradingView
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Beats Estimates by 28.7% Amid Uncertain Revenue PictureEnergy Earnings Report - dars.gov.et
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds - Sahm
InterCure secures $7.4M funding commitment, may rise to $18.6M - Investing.com UK
InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors. - marketscreener.com
InterCure Secures NIS 22 Million Private Placement to Fund Global Medical Cannabis Expansion - TipRanks
InterCure secures $7.4M funding commitment, may rise to $18.6M By Investing.com - Investing.com South Africa
InterCure (NASDAQ: INCR) lines up NIS 22–54 million private placement funding - Stock Titan
InterCure raises NIS 22M, with room to reach NIS 54M - Stock Titan
InterCure Ltd (INCR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InterCure Ltd (INCR) Institutional Confidence - TradingKey
InterCure Ltd (INCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InterCure Ltd (INCR) Valuation: PE, PB & Fair Value Analysis - TradingKey
InterCure Ltd (INCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InterCure Ltd (INCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InterCure Ltd (INCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InterCure Ltd (INCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InterCure Ltd (INCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
INCR Q2 2023 Earnings: EPS Surpasses Estimates on Operational StrengthEarnings Sentiment Score - Bölüm Sonu Canavarı
InterCure Advances Global Push With Botanico Acquisition Tranche and U.S. Strategy Review - The Globe and Mail
InterCure completes Botanico acquisition and expands into U.S. medical cannabis - MMJDaily
InterCure Initiates Review of US Medical Cannabis Opportunities Following Federal Rescheduling - Cannabis Business Times
InterCure completes first tranche of Botanico acquisition By Investing.com - Investing.com South Africa
InterCure Ltd. Completes First Tranche of Botanico Acquisition to Enhance International Medical Cannabis Platform - Moomoo
InterCure (NASDAQ: INCR) advances Botanico deal and eyes U.S. medical cannabis - Stock Titan
InterCure Initiates Strategic Review of U.S. Medical - GlobeNewswire
U.S. cannabis shift prompts InterCure rethink and new launches in Germany - Stock Titan
InterCure Ltd. completed the acquisition of 50% stake in Botanico Ltd. - marketscreener.com
Intercure Ltd. (INCR) Holds Near Support as Modest Gains Signal Stabilization AttemptRevenue Weighted - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates by Nearly 29%, Yet Stock Sheds ValueSegment Revenue Breakdown - newsline.com
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Beats Estimates by 28.68% Amidst Revenue Uncertainty - dars.gov.et
INCR Q2 2023 Earnings: EPS Surpasses Estimates by 28.7%, Driving Stock HigherPositive Surprise Momentum - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates, Stock Declines Amid Broader Market HeadwindsRevenue Surprise History - dars.gov.et
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Beat Drives 12.15% Stock SurgeEnergy Earnings Report - newsline.com
INCR Q2 2023 Earnings: EPS Surpasses Estimates by 28.68%Debt Analysis Report - The Legal Advocate
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Surges Past Estimates, Stock RalliesSurprise Factor Analysis - The Legal Advocate
Intercure Ltd. Shares Surge Over 15% as Cannabis Sector Sees Renewed InterestThrowback Trade - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates as Profitability StrengthensProfit Warning Alert - The Legal Advocate
Intercure Ltd. (INCR) Rallies 5.57% as It Approaches Key Resistance LevelRSI Oversold Picks - The Legal Advocate
INCR Q2 2023 Earnings: Strong EPS Beat Highlights Operational EfficiencyEarnings Analysis - thelegaladvocate.com
INCRIntercure Ltd Stock Price and Quote - Finviz
Intercure Ltd. (INCR) Rallies 4.8%: Testing Key Resistance at $0.97Risk Reward Setups - newsline.com
INCR Q2 2023 Earnings: EPS Beat Surprises by 28.7% Despite Revenue UncertaintyShare Repurchase Impact - dars.gov.et
INCR Q2 2023 Earnings: EPS Surges Past Estimates as Company Delivers Strong Operational ResultsEarnings Trend Analysis - Newser
Intercure Ltd Stock (INCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.50%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):